Clinical and commercial roadmap
Clinical Development & Commercialisation Pathway.
Virax Biolabs is advancing ViraxImmune™ through a staged clinical, regulatory and commercial development pathway. The roadmap summarises current activities and target milestones.
View Near-Term Commercial Strategy
For clinicians
Validation, utility, and evidence milestones
For investors
Regulatory, launch, and commercialisation visibility
STRATEGIC TIMELINE
Development & Commercialisation Milestones.
Our strategic pathway balances completed clinical foundations with long-term regulatory milestones. This roadmap outlines our pipeline from initial multi-center data collection through to planned commercial market entry, with future phases remaining dependent upon ongoing clinical data, regulatory feedback, and operational progress.
2025
2026
2027 (Target)
2028 (Target)
Platform Foundation
Assay Architecture & UK Study-Site Activation
Established initial assay architecture and optimisation protocols, alongside clinical sample collection across active UK study sites and preparation for additional US clinical programmes.
Clinical validation in progress
Ongoing Assay Optimisation & Multi‑Centre Evidence Generation
Continued optimisation of assay workflows and analytical parameters, alongside multi‑centre clinical sample collection and early‑stage evidence generation across active UK and US study sites.
Planned initial US market entry
Planned US Laboratory-Developed Test Pathway
Targeted commercial introduction through a US laboratory-developed test model.
Potential broader AUTHORISATION
Potential FDA De Novo / IVD Pathway
Potential progression towards an FDA De Novo submission for a standardised IVD.
Future milestones depend on development and validation results, laboratory readiness and applicable regulatory requirements.
STRATEGIC TIMELINE
Near-term commercial & market launch strategy
While advancing ViraxImmune™ through clinical and regulatory development, Virax Biolabs is commercialising ImmuneSelect research-use-only products and developing specialised laboratory-service capabilities. These activities are intended to support early revenue generation, commercial infrastructure and a more resilient operating foundation ahead of a potential diagnostic launch.
Explore Research Solutions